EFElin Forsgren

Elin Forsgren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elin Forsgren has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Annika Pasanen

    Department of Oncology Helsinki University Comprehensive Cancer Centre Helsinki Finland

    1 shared publication
  • Daniel Molin

    Department of Immunology, Genetics and Pathology, Cancer Immunotherapy Uppsala University Uppsala Sweden

    1 shared publication
  • Gunilla Enblad

    Department of Immunology, Genetics and Pathology, Cancer Immunotherapy Uppsala University Uppsala Sweden

    1 shared publication
  • Hanne Kuitunen

    Department of Oncology Oulu University Hospital Oulu Finland

    1 shared publication
  • Hans Bentzen

    Department of Haematology Aarhus University Hospital Aarhus Denmark

    1 shared publication
  • Ingrid Glimelius

    Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden

    1 shared publication

Latest Publications

  • Open Access

    Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long‐term follow‐up of the Nordic Lymphoma Group MCL6 Philemon trial

    by Elin Forsgren, Rasmus R. K. Jørgensen, Hans Bentzen, Jon Riise, Jacob Haaber, Annika Pasanen, Hanne Kuitunen, Karin F. Wader, Tarec C. El‐Galaly, Martin Hutchings, et al.

    Relapsed or refractory mantle cell lymphoma (R/R MCL) remains difficult to treat, with outcomes dependent on the treatment regimen and remission duration after first‐line therapy. Several non‐chemotherapeutic regimens are under evaluation in R/R, but few studies report long‐term outcomes. In this study, we present the long‐term outcomes of the 50 patients treated with ibrutinib, lenalidomide, and rituximab (IR2) in the Nordic Lymphoma Group MCL6 Philemon phase 2 trial. Survival outcomes were compared with a matched cohort from the Swedish MCLcomplete study. After 5 years, 14 patients (28%) remained relapse‐free, including one with a TP53 mutation. The median progression‐free survival (PFS) was 17.4 months, with the longest PFS of 8.1 years. Thirty‐two patients had died, primarily from MCL (72%). Poorer survival was associated with intermediate or high‐risk Mantle Cell Lymphoma International Prognostic Index and impaired health‐related quality of life (HRQoL). While TP53 mutations (n = 11) did not significantly impact survival, a trend toward poorer outcomes was observed in multivariable Cox regression analyses (PFS hazard ratio: 2.09, 95% confidence interval: 0.95–4.62, p = 0.068). The IR2 regimen demonstrated superior survival compared to the MCLcomplete cohort both before and after matching. In conclusion, this study highlights the role of non‐chemotherapeutic agents in R/R MCL and demonstrates the prognostic impact of HRQoL on overall survival. Although IR2 showed initial activity in TP53‐mutated patients, it did not completely overcome their poor prognosis. However, the IR2 regimen may serve as a bridge to allogeneic stem cell transplantation or chimeric antigen receptor T‐cell therapy.


  • Open Access

    Evaluation of coverage, generalisability and validity of the U‐CAN lymphoma biobank in Sweden: A comparison with nationwide registers

    by Elin Forsgren, Sara Ekberg, Karin E. Smedby, Patrick Nylund, Tobias Sjöblom, Max Flogegård, Sara Sjöström, Magnus Hultdin, Karin Hallén, Mats Hellström, et al.

    Summary: Validation of biobanks and large cancer cohorts is essential in ensuring high‐quality research results. We examined the coverage, generalisability and validity of the lymphoma collection of the Uppsala‐Umeå Comprehensive Cancer Consortium (U‐CAN) biobank in Sweden, one of the largest cancer biobanks in Europe. Up until 2022, 889 lymphoma patients in U‐CAN Uppsala had available samples, and 329 in U‐CAN Umeå. Patients diagnosed in the U‐CAN Uppsala area 2011–2021 (n = 843) were linked to the nationwide Swedish Lymphoma Register, and a subset diagnosed before 2019 (n = 727) to population‐based registers. The coverage was 39% of all lymphoma patients between 2011 and 2019 diagnosed in the U‐CAN Uppsala area, with a pandemic decline to 10% during 2020–2021. The patients included had superior overall survival (hazard ratio = 0.70 [95% confidence interval, CI: 0.60–0.82]) than all lymphoma patients in Sweden. They had better performance status, were younger (odds ratio [OR] = 0.21 [95% CI: 0.13–0.34]) and had less comorbidities (OR = 0.66 [95% CI: 0.56–0.78]). However, cause‐specific survival and stage distribution were similar. The questionnaire data captured less comorbidities compared to the national registers. Evaluations of biobanks are important, as even population‐based biobanks such as U‐CAN select younger patients with higher socioeconomical status and better performance status. However, the similar cause‐specific survival as in the registries suggests U‐CANs usefulness for prognostic biomarker studies.